Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bavarian Shares Advance After FDA Approves Cancer Vaccine Trial

Don't Miss Out —
Follow us on:

Dec. 8 (Bloomberg) -- Bavarian Nordic A/S, which is testing a prostate cancer vaccine, rose as much as 6.5 percent in Copenhagen trading after getting U.S. approval to proceed with the last trial required of the experimental medicine.

The U.S. Food and Drug Administration has reviewed and approved the trial’s design and goals in a special protocol assessment, the Kvistgaard, Denmark-based drugmaker said today.

Bavarian Nordic has received proposals from companies interested in licensing the vaccine. Last week, Juergen Langhaerig, head of business development, said a “mid-to high-single-digit” number of drugmakers had submitted term sheets outlining their offers. The approval means Bavarian can move ahead with the study as planned, it said today.

If the drug, named Prostvac, gets to the market it would compete against Dendreon Corp.’s Provenge, the first medicine to build up the body’s immune system to attack cancer cells. Provenge may generate as much as $1.75 billion in 2014 if the U.S. government agrees to pay for the $93,000 treatment, a Bloomberg survey of analysts showed.

Bavarian gained 8.50 kroner, or 3.8 percent, to 233 kroner at 12:38 p.m. The stock has climbed 72 percent in the past 12 months, beating the Bloomberg Europe Pharmaceutical Index, which has gained 7.4 percent.

To contact the reporter on this story: Frances Schwartzkopff in Copenhagen at fschwartzko1@bloomberg.net

To contact the editor responsible for this story: Angela Cullen at acullen8@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.